Skip to main content
PMC home page
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 1996 Jul;34(7):1849–1853. doi: 10.1128/jcm.34.7.1849-1853.1996

Interlaboratory comparison of sequence-specific PCR and ligase detection reaction to detect a human immunodeficiency virus type 1 drug resistance mutation. The AIDS Clinical Trials Group Virology Committee Drug Resistance Working Group.

R W Shafer 1, M A Winters 1, D L Mayers 1, A J Japour 1, D R Kuritzkes 1, O S Weislow 1, F White 1, A Erice 1, K J Sannerud 1, A Iversen 1, F Pena 1, D Dimitrov 1, L M Frenkel 1, P S Reichelderfer 1
PMCID: PMC229135  PMID: 8784610

Abstract

Sequence-specific PCR was used in six laboratories and a ligase detection reaction was used in one laboratory to detect the zidovudine-resistance mutation at codon 215 of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase DNA. The genotypes of 27 different clinical samples, including cultured HIV-1 isolates, peripheral blood mononuclear cells, and plasma, were correctly identified by 140 of 154 (91%) assays. The sensitivity for detecting a mutation was 96% for HIV-1 reverse transcriptase DNA clone mixtures containing 30% mutant DNA and 62% for mixtures containing 6% mutant DNA.

Full Text

The Full Text of this article is available as a PDF (231.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Boucher C. A., O'Sullivan E., Mulder J. W., Ramautarsing C., Kellam P., Darby G., Lange J. M., Goudsmit J., Larder B. A. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J Infect Dis. 1992 Jan;165(1):105–110. doi: 10.1093/infdis/165.1.105. [DOI] [PubMed] [Google Scholar]
  2. D'Aquila R. T., Johnson V. A., Welles S. L., Japour A. J., Kuritzkes D. R., DeGruttola V., Reichelderfer P. S., Coombs R. W., Crumpacker C. S., Kahn J. O. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group. Ann Intern Med. 1995 Mar 15;122(6):401–408. doi: 10.7326/0003-4819-122-6-199503150-00001. [DOI] [PubMed] [Google Scholar]
  3. Eastman P. S., Boyer E., Mole L., Kolberg J., Urdea M., Holodniy M. Nonisotopic hybridization assay for determination of relative amounts of genotypic human immunodeficiency virus type 1 zidovudine resistance. J Clin Microbiol. 1995 Oct;33(10):2777–2780. doi: 10.1128/jcm.33.10.2777-2780.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Erice A., Balfour H. H., Jr Resistance of human immunodeficiency virus type 1 to antiretroviral agents: a review. Clin Infect Dis. 1994 Feb;18(2):149–156. doi: 10.1093/clinids/18.2.149. [DOI] [PubMed] [Google Scholar]
  5. Frenkel L. M., Wagner L. E., 2nd, Atwood S. M., Cummins T. J., Dewhurst S. Specific, sensitive, and rapid assay for human immunodeficiency virus type 1 pol mutations associated with resistance to zidovudine and didanosine. J Clin Microbiol. 1995 Feb;33(2):342–347. doi: 10.1128/jcm.33.2.342-347.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Gingeras T. R., Prodanovich P., Latimer T., Guatelli J. C., Richman D. D., Barringer K. J. Use of self-sustained sequence replication amplification reaction to analyze and detect mutations in zidovudine-resistant human immunodeficiency virus. J Infect Dis. 1991 Dec;164(6):1066–1074. doi: 10.1093/infdis/164.6.1066. [DOI] [PubMed] [Google Scholar]
  7. Japour A. J., Welles S., D'Aquila R. T., Johnson V. A., Richman D. D., Coombs R. W., Reichelderfer P. S., Kahn J. O., Crumpacker C. S., Kuritzkes D. R. Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. AIDS Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance Working Group. J Infect Dis. 1995 May;171(5):1172–1179. doi: 10.1093/infdis/171.5.1172. [DOI] [PubMed] [Google Scholar]
  8. Kaye S., Comber E., Tenant-Flowers M., Loveday C. The appearance of drug resistance-associated point mutations in HIV type 1 plasma RNA precedes their appearance in proviral DNA. AIDS Res Hum Retroviruses. 1995 Oct;11(10):1221–1225. doi: 10.1089/aid.1995.11.1221. [DOI] [PubMed] [Google Scholar]
  9. Kaye S., Loveday C., Tedder R. S. A microtitre format point mutation assay: application to the detection of drug resistance in human immunodeficiency virus type-1 infected patients treated with zidovudine. J Med Virol. 1992 Aug;37(4):241–246. doi: 10.1002/jmv.1890370402. [DOI] [PubMed] [Google Scholar]
  10. Kozal M. J., Shafer R. W., Winters M. A., Katzenstein D. A., Merigan T. C. A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients. J Infect Dis. 1993 Mar;167(3):526–532. doi: 10.1093/infdis/167.3.526. [DOI] [PubMed] [Google Scholar]
  11. Kwok S., Chang S. Y., Sninsky J. J., Wang A. A guide to the design and use of mismatched and degenerate primers. PCR Methods Appl. 1994 Feb;3(4):S39–S47. doi: 10.1101/gr.3.4.s39. [DOI] [PubMed] [Google Scholar]
  12. Larder B. A., Kellam P., Kemp S. D. Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. AIDS. 1991 Feb;5(2):137–144. doi: 10.1097/00002030-199102000-00002. [DOI] [PubMed] [Google Scholar]
  13. Richman D. D., Havlir D., Corbeil J., Looney D., Ignacio C., Spector S. A., Sullivan J., Cheeseman S., Barringer K., Pauletti D. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol. 1994 Mar;68(3):1660–1666. doi: 10.1128/jvi.68.3.1660-1666.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Richman D. D. Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Antimicrob Agents Chemother. 1993 Jun;37(6):1207–1213. doi: 10.1128/aac.37.6.1207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Schuurman R., Nijhuis M., van Leeuwen R., Schipper P., de Jong D., Collis P., Danner S. A., Mulder J., Loveday C., Christopherson C. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis. 1995 Jun;171(6):1411–1419. doi: 10.1093/infdis/171.6.1411. [DOI] [PubMed] [Google Scholar]
  16. Shafer R. W., Kozal M. J., Winters M. A., Iversen A. K., Katzenstein D. A., Ragni M. V., Meyer W. A., 3rd, Gupta P., Rasheed S., Coombs R. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. J Infect Dis. 1994 Apr;169(4):722–729. doi: 10.1093/infdis/169.4.722. [DOI] [PubMed] [Google Scholar]
  17. Shafer R. W., Merigan T. C. HIV virology for clinical trials. AIDS. 1995;9 (Suppl A):S193–S202. [PubMed] [Google Scholar]
  18. St Clair M. H., Martin J. L., Tudor-Williams G., Bach M. C., Vavro C. L., King D. M., Kellam P., Kemp S. D., Larder B. A. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science. 1991 Sep 27;253(5027):1557–1559. doi: 10.1126/science.1716788. [DOI] [PubMed] [Google Scholar]
  19. Tada M., Omata M., Kawai S., Saisho H., Ohto M., Saiki R. K., Sninsky J. J. Detection of ras gene mutations in pancreatic juice and peripheral blood of patients with pancreatic adenocarcinoma. Cancer Res. 1993 Jun 1;53(11):2472–2474. [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES